Chronic wounds are defined clinically as injuries that fail to progress through the normal phases of healing within a month’s time, leading to prolonged inflammation and tissue degradation. Affecting roughly 12 million people globally each year—and nearly 4.5 million in the United States alone—these wounds impose enormous burdens on healthcare systems and severely impact patients’ quality of life. Approximately 20% of individuals suffering from chronic wounds ultimately face amputation, underscoring the urgent need for therapeutic innovations that target the underlying biological obstacles to healing.

Central to the pathology of chronic wounds is hypoxia, a state of insufficient oxygen within the deepest layers of tissue affected by injury. When oxygen supply from the bloodstream and ambient air fails to reach these regions, healing stalls. Hypoxia extends the inflammatory phase, promotes bacterial colonization, and impairs regeneration, creating an environment where wounds become stagnant or worsen. Addressing the hypoxic microenvironment has remained an elusive challenge for clinicians and bioengineers alike.

The novel hydrogel developed by the UC Riverside team, led by Associate Professor of Bioengineering Iman Noshadi, offers a strategic solution by delivering oxygen directly within the wound matrix. Unlike conventional treatments that apply oxygen superficially or intermittently, this self-oxygenating gel integrates a choline-based liquid that is inherently antibacterial, biocompatible, and nontoxic, embedded within a water-rich soft polymer network. This innovative matrix conforms intimately to the unique 3D architecture of wounds, filling crevices and delivering oxygen precisely where it is most critically needed.

A remarkable feature of the hydrogel is its electrochemical oxygen generation capability. Activated by a miniature battery akin to those found in hearing aids, the gel functions as a microscale electrochemical system that catalyzes water-splitting reactions. This process gradually releases oxygen over extended periods, unlike traditional approaches providing only temporary relief. The sustained oxygenation, lasting up to a month under experimental conditions, supports continuous progression through the healing stages—especially vascularization, where formation of new blood vessels is vital.

Preclinical testing in diabetic and elderly murine models—carefully selected for their close physiological resemblance to human chronic wound pathology—has demonstrated the gel’s profound therapeutic impact. Untreated wounds in these models typically fail to close and are associated with high mortality rates. However, wounds treated weekly with the oxygen-generating hydrogel closed within approximately 23 days, representing a significant survival benefit. This sets a promising precedent for translation into human clinical applications.

Beyond oxygen delivery, the gel’s incorporation of choline imparts additional immunomodulatory benefits. Chronic wounds often experience elevated production of reactive oxygen species (ROS), chemically unstable molecules that exacerbate cellular damage and prolong inflammation. By providing stable oxygen while simultaneously tempering the immune system’s overactive responses, the hydrogel restores molecular balance within the wound microenvironment, mitigating oxidative stress and fostering conditions conducive to tissue regeneration.

Current wound care products—such as absorbent dressings or antimicrobial agents—primarily target symptom management, fluid control, or infection prevention but inadequately address the fundamental issue of hypoxia. The UC Riverside gel distinguishes itself by confronting the root cause with a bioelectrochemical strategy that integrates material science and cellular biology. This represents a paradigm shift in how chronic wounds can be therapeutically managed to restore natural healing trajectories rather than merely controlling complications.

The implications of this technology extend far beyond wound care alone. Oxygen and nutrient transport are critical hurdles in the broader field of tissue engineering and regenerative medicine, particularly in efforts to cultivate functional replacement tissues or organs. As engineered tissues increase in thickness, diffusion limits impose strict constraints on cellular viability. The oxygen-generating gel’s capacity to provide stable and localized oxygenation offers an innovative platform that could be adapted to sustain complex 3D tissue constructs, potentially bridging a gap toward clinically viable organ manufacturing.

Despite the gel’s promise, systemic societal challenges such as rising diabetes prevalence, aging demographics, and sedentary lifestyles continue to underscore the multifactorial nature of chronic wounds. As Baishali Kanjilal, a bioengineer involved in the project, explains, these trends compound immune dysfunction and complicate healing from a physiological standpoint. Nevertheless, this novel biomaterial innovation provides hope by furnishing the body with a critical missing element in the healing equation, potentially reducing amputations and improving long-term outcomes.

Looking ahead, the research team envisions evolving the technology into a deployable product, where the oxygen-generating gel could be periodically replenished to maintain therapeutic oxygen levels over extended periods. This ongoing delivery system could revolutionize how chronic wounds are treated in clinical practice, shifting from episodic interventions to continuous, tailored management. Given its biocompatibility, ease of application, and mechanistic advantages, this hydrogel stands at the forefront of next-generation biomaterials for wound repair.

In an era where bioengineering is increasingly integral to medical innovation, the UC Riverside oxygen-delivering hydrogel embodies the intersection of sophisticated electrochemistry, immunology, and material science, poised to address a pressing unmet clinical need. By directly resolving hypoxia and modulating inflammation, it offers a scientifically sound and translationally applicable solution to a pervasive health challenge, heralding a new chapter in regenerative therapies.

Subject of Research: Self-oxygenating hydrogel for chronic wound healing
Article Title: Electrochemical Hydrogel Patch for Sustained Oxygen Delivery in Chronic Wounds
News Publication Date: January 5, 2026
Web References: https://www.nature.com/articles/s43246-025-00947-4, http://dx.doi.org/10.1038/s43246-025-00947-4
Image Credits: Iman Noshadi/UCR

Keywords

Wound healing, Tissue repair, Diabetes, Autoimmune disorders, Type 1 diabetes, Type 2 diabetes, Diseases and disorders, Health and medicine, Bioengineering, Biomedical engineering, Biomaterials, Regenerative medicine, Tissue engineering, Aging populations

Melding innovative biomaterials with cellular therapies, this research builds on the intrinsic properties of mesenchymal stem cells, which are well known for their ability to differentiate into various cell types and secrete a multitude of growth factors. These factors are crucial for tissue repair and the reduction of inflammation. The integration of PMSCs into a biocompatible hydrogel matrix allows for targeted delivery and sustained release of these therapeutic agents directly at the site of damage, facilitating a more effective healing process.

The methodology of this clinical trial is particularly noteworthy. A carefully curated sample of participants was subjected to the rigorous standards of a randomized controlled trial. With patients receiving either the PMSC-embedded hydrogel or a placebo, the research team meticulously tracked healing progress using various clinical assessments and biomarkers. This dual-approach not only underscores the commitment to scientific rigor but also ensures that the findings would be robust and applicable to a broader patient population.

As part of the trial, participants were monitored over several weeks, with assessments occurring at predetermined intervals. The data collection focused on a variety of parameters, including the rate of epithelialization, the degree of inflammation, and patient-reported outcomes regarding pain and quality of life. Not only did researchers prioritize objective clinical measures, but they also sought to gauge the subjective experiences of participants, thereby enriching the data with holistic insights.

One of the most compelling findings from the study was the demonstrable speed of recovery in patients receiving the PMSC hydrogel treatment compared to those on placebo. Participants treated with the experimental hydrogel exhibited significant improvements in skin integrity and comfort levels, suggesting that the stem cell therapy may not only expedite healing but also alleviate some of the pain and discomfort associated with traditional recovery methods.

The clinical trial’s results have garnered attention from the scientific community, as they collectively suggest that the PMSC-embedded hydrogel could redefine the landscape of post-radiation care. By focusing on local application rather than systemic treatment, this innovative approach minimizes potential side effects often related to broader therapeutic interventions, thus presenting a safer alternative for vulnerable patients.

The implications of this research extend beyond mere treatment efficacy. By illustrating the potential of placental mesenchymal stem cells, the study opens avenues for further exploration into their applications across various medical fields, including dermatology and plastic surgery. The regenerative capabilities of these stem cells, demonstrated in their use to repair radiation-induced skin injuries, could potentially be adapted to treat other dermatological conditions, or even enhance the outcomes of surgical procedures.

Moreover, the findings may catalyze further research into optimizing the hydrogel formulation. The study’s authors indicated a keen interest in enhancing the gel’s properties to improve cell retention and extend the lifespan of the released growth factors. Such advancements would ultimately bolster the gel’s effectiveness, making it a pivotal tool not just for skin damage but potentially for a range of other muscular or tissue injuries that warrant expedited healing.

The commitment to advancing science in this space has also spurred an exploration of different types of stem cells, beyond those derived from the placenta. Investigating other sources like adipose tissue or bone marrow could further enrich the understanding of how various stem cell types interact with diverse biomaterials. Such explorations could lead to customizable treatments tailored to individual patient needs, resonating with the movement towards personalized medicine.

Interestingly, the study highlights not only the promise of this treatment but also the ethical considerations of using placental tissue. Experts have begun to discuss the ethical procurement of such materials, ensuring that their use respects donor rights while harnessing the potential benefits that placental-derived products can offer. These considerations serve as a reminder that as science progresses, it must do so responsibly, ever mindful of the implications and responsibilities toward both patients and sources.

With the positive outcomes of this double-blind trial, it is likely that regulatory bodies will take swift notice of these findings. The path towards potential FDA approval could begin, presenting a transformative moment for patients who have long suffered from the side effects of radiation therapy. If further studies confirm these initial results, we may soon see the PMSC hydrogel approach accepted as part of clinical practice, altering how skin damage related to radiation is managed in healthcare settings.

As excitement builds around these findings, it serves as a testament to the power of innovation and collaboration in the field of regenerative medicine. The intersection of technology, biology, and material science has yielded significant progress in understanding how we can leverage the body’s innate healing mechanisms to address complex medical issues. The journey from research to application may be challenging, but the potential benefits are vast, igniting hope in patients and advocates alike.

In conclusion, the double-blind randomized phase II clinical trial underscores the promising potential of a placental mesenchymal stem cell-embedded hydrogel in treating radiation-induced skin damage. This remarkable research not only enhances our understanding of cell therapy in clinical settings but also opens the door to future innovations that could improve patient outcomes across various therapeutic arenas. As the scientific community eagerly anticipates the next steps in this research, it is clear that the integration of stem cell biology and biomaterial science holds immense promise for shaping the future of regenerative medicine.

Subject of Research: Application of placental mesenchymal stem cell-embedded biomaterial hydrogel in repairing radiation-induced skin damage.

Article Title: Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial.

Article References:

Tian, L., Han, Z., Jiang, M. et al. Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial.
J Transl Med 23, 1057 (2025). https://doi.org/10.1186/s12967-025-07060-7

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07060-7

Keywords: placental mesenchymal stem cells, hydrogel, radiation-induced skin damage, regenerative medicine, clinical trial.